GSK plc position in BCYC
BICYCLE THERAPEUTICS PLC · Health Care
GSK plc reported holding 1,529,561 shares of BCYC (BICYCLE THERAPEUTICS PLC) in its Q3 2026 13F filing — a position valued at US$5.6M, representing 1.13% of its reported portfolio and ranking #11 among its reported holdings. GSK plc has disclosed BCYC holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR
How GSK plc's BCYC position evolved
GSK plc first disclosed a stake in BCYC in Q4 2025 at 1,529,561 shares (US$10.8M). Across 4 filings, GSK plc held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,529,561 shares valued at US$5.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.53M | $10.83M | New |
| Q1 2026 | 1.53M | $7.10M | Hold |
| Q2 2026 | 1.53M | $6.49M | Hold |
| Q3 2026 | 1.53M | $5.63M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BCYC and 13F data
BCYC (BICYCLE THERAPEUTICS PLC) is a Health Care company. 10 other funds we track also report a position in BCYC — the largest reported positions include BAKER BROS. ADVISORS LP (US$46.2M), FCPM III SERVICES B.V. (US$14.7M), Long Focus Capital Management, LLC (US$14.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BCYC
- BAKER BROS. ADVISORS LP 10.89M sh · $46.15M · Q2 2026
- FCPM III SERVICES B.V. 3.47M sh · $14.71M · Q2 2026
- Long Focus Capital Management, LLC 3.31M sh · $14.04M · Q2 2026
FAQ
How long has GSK plc held BCYC?
GSK plc has disclosed BCYC holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is GSK plc's current position in BCYC?
As of Q3 2026, GSK plc holds 1.53M shares of BCYC (BICYCLE THERAPEUTICS PLC), valued at $5.63M, representing 1.13% of its reported portfolio and ranking #11.
Has GSK plc been buying or selling BCYC?
In the latest 13F filing (Q3 2026), GSK plc held unchanged its position in BCYC.
Which other funds hold BCYC?
Other major institutional holders of BCYC include BAKER BROS. ADVISORS LP, FCPM III SERVICES B.V., Long Focus Capital Management, LLC, among 10 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.